OMass Therapeutics is an early-stage drug discovery company specialized in applying state of the art biophysical platform technologies to discover therapies for severe unmet medical needs in immunology and genetically defined disorders. The company was founded by Professor Dame Carol Robinson to leverage her pioneering work in native mass spectrometry, in studies of dynamic protein assemblies, to characterise challenging drug targets including membrane proteins. The high resolution of our biophysical platform offers an unprecedented advantage in the detection of drug leads.
The company vision is to build an integrated drug discovery company, with biophysical platform technologies at its core, and develop a pipeline of novel therapies. Our ambition is to develop and ultimately commercialise our products.
Following successful Series A funding, the company is expanding significantly in different areas. This is an excellent time to join a dynamic growing company.
OMass Therapeutics is inviting applications for the position of Scientist to work within the mass spectrometry screening team. The company offers a thriving and creative environment for a well-suited candidate to become an integral part of our future vision.
The successful candidate will be an early-stage scientist with a good understanding of mass spectrometry, preferably using LC-MS based methods for identification of small molecules. You will be responsible for using MS based platforms for the analysis of membrane proteins and their interactions with small molecules. Experience of molecular biology, protein expression/purification is advantageous. The role is based in our Oxford site.
Applications to be received by 9am (BST) Monday 4th October 2021
